Conjugation of recombinant human deoxyribonuclease I (rhDNase) to polyethylene glycol (PEG) of 20 to 40 kDa was previously shown to prolong the residence time of rhDNase in the lungs of mice after pulmonary delivery while preserving its full enzymatic activity. This work aimed to study the fate of native and PEGylated rhDNase in the lungs and to elucidate their biodistribution and elimination pathways after intratracheal instillation in mice. In vivo fluorescence imaging revealed that PEG30 kDa-conjugated rhDNase (PEG30-rhDNase) was retained in mouse lungs for a significantly longer period of time than native rhDNase (12 days vs 5 days). Confocal microscopy confirmed the presence of PEGylated rhDNase in lung airspaces for at least 7 days. I...
PEGylation is a promising approach to increase the residence time of antibody fragments in the lungs...
In the field of therapeutic proteins, monoclonal antibodies (mAbs) are gaining momentum as an import...
lar therapy via direct intratracheal delivery has gained interest as a novel therapeutic strategy fo...
Conjugation of recombinant human deoxyribonuclease I (rhDNase) to polyethylene glycol (PEG) of 20 to...
Conjugation of recombinant human deoxyribonuclease I (rhDNase) to large (≥ 20 kDa) polyethylene glyc...
Conjugation to high molecular weight (MW) polyethylene glycol (PEG) was previously shown to largely ...
Conjugation to high molecular weight (MW >= 20 kDa) polyethylene glycol (PEG) was previously shown t...
Highly viscous mucus and its impaired clearance characterize the lungs of patients with cystic fibro...
Recombinant human deoxyribonuclease I (rhDNase) is the mucolytic agent most widely used in cystic fi...
Recombinant human deoxyribonuclease I (rhDNase) is the mucolytic agent most widely used for the trea...
Recombinant human deoxyribonuclease I (rhDNase, Pulmozyme®) is the most frequently used mucolytic ag...
The PEGylation of antibody fragments has been shown to greatly prolong their residence time in the l...
Recombinant human deoxyribonuclease I (rhDNase, Pulmozyme®) is the most frequently used mucolytic ag...
Pulmonary administration of anti-cytokine antibodies offers a targeted therapy in asthma. However, t...
More and more therapeutic proteins are developed for an administration by inhalation to treat respir...
PEGylation is a promising approach to increase the residence time of antibody fragments in the lungs...
In the field of therapeutic proteins, monoclonal antibodies (mAbs) are gaining momentum as an import...
lar therapy via direct intratracheal delivery has gained interest as a novel therapeutic strategy fo...
Conjugation of recombinant human deoxyribonuclease I (rhDNase) to polyethylene glycol (PEG) of 20 to...
Conjugation of recombinant human deoxyribonuclease I (rhDNase) to large (≥ 20 kDa) polyethylene glyc...
Conjugation to high molecular weight (MW) polyethylene glycol (PEG) was previously shown to largely ...
Conjugation to high molecular weight (MW >= 20 kDa) polyethylene glycol (PEG) was previously shown t...
Highly viscous mucus and its impaired clearance characterize the lungs of patients with cystic fibro...
Recombinant human deoxyribonuclease I (rhDNase) is the mucolytic agent most widely used in cystic fi...
Recombinant human deoxyribonuclease I (rhDNase) is the mucolytic agent most widely used for the trea...
Recombinant human deoxyribonuclease I (rhDNase, Pulmozyme®) is the most frequently used mucolytic ag...
The PEGylation of antibody fragments has been shown to greatly prolong their residence time in the l...
Recombinant human deoxyribonuclease I (rhDNase, Pulmozyme®) is the most frequently used mucolytic ag...
Pulmonary administration of anti-cytokine antibodies offers a targeted therapy in asthma. However, t...
More and more therapeutic proteins are developed for an administration by inhalation to treat respir...
PEGylation is a promising approach to increase the residence time of antibody fragments in the lungs...
In the field of therapeutic proteins, monoclonal antibodies (mAbs) are gaining momentum as an import...
lar therapy via direct intratracheal delivery has gained interest as a novel therapeutic strategy fo...